首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1508765

肾癌药物市场：依治疗方法、按药理学、按分销管道、按地区

Kidney Cancer Drugs Market, By Therapy: Targeted Therapy, Immunotherapy, and Chemotherapy, By Pharmacological Class: Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines, and Others, By Distribution Channel, By Geography

出版日期: 2024年06月10日 | 出版商:

Coherent Market Insights | 英文 173 Pages | 商品交期: 2-3个工作天内

价格

简介目录

肾癌治疗市场预计到2024年将达到68.9亿美元，预计到2031年将达到103.1亿美元，2024年至2031年的复合年增长率为5.9%。

图 1. 2024 年肾癌治疗市场占有率（按地区划分）

药物分析检测是指利用科学技术和方法来判定肾癌（又称肾细胞癌）。肾癌正成为全世界最常见的癌症之一。据估计，全球每年诊断出超过 40 万例新病例。与肾癌相关的危险因子包括吸烟、肥胖、遗传因素和接触某些毒素。早期肾癌可能没有任何症状，但有些患者可能会出现尿血、体侧疼痛或腹部肿块。治疗选择范围从局部疾病的部分或根治性切除术到针对晚期疾病的标靶治疗和免疫治疗。总体而言，由于发病率上升、患者获得先进治疗的机会增加以及强大的新药研发等因素将继续支持市场成长，全球肾癌治疗市场预计在未来几年将出现成长。

市场动态：

全球肾癌治疗市场是由全球肾细胞癌盛行率上升所推动的。人口老化、肥胖率上升以及职场毒素暴露增加等风险因素不断增加，导致疾病发生率上升。此外，已开发国家患者获得优质标靶治疗和免疫疗法的机会的增加正在支持市场成长。同时，由于手术、放射治疗和药物治疗等治疗时间较长，患者越来越依赖维持治疗。儘管市场存在有利的成长机会，但关键药物专利到期和学名药进入市场等因素可能会阻碍大型药物开发商的收益来源。此外，新兴市场的高定价和承受能力问题限制了进入更广大市场的机会。然而，针对各种疾病途径的临床试验中有大量的分子，具有未来市场扩张的潜力。

本研究的主要特点

该报告对全球肾癌治疗市场进行了详细分析，并以2023年为基准年，分析了预测期（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。。
它还揭示了各个细分市场的潜在收益成长机会，并说明了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
根据公司亮点、产品系列、主要亮点、绩效和策略等参数，对全球肾癌治疗药物市场的主要企业进行概况分析。
该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
全球肾癌治疗药物市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于全球肾癌治疗药物市场分析的各种策略矩阵，将有助于相关人员做出决策。

公司简介
- Pfizer Inc.
- 3D Systems
- Novartis AG
- Bristol-Myers Squibb Company
- Roche Holding AG（Genentech, Inc.）
- Bayer AG
- Exelixis, Inc.
- Merck &Co., Inc.
- Eisai Co., Ltd.
- Aveo Pharmaceuticals
- AstraZeneca PLC
- Ipsen Biopharmaceuticals, Inc.
- GlaxoSmithKline plc
- Abbott Laboratories Source
- Amgen Inc.
- Calithera Biosciences, Inc.
- Active Biotech
- Immatics Biotechnologies GmbH
- Karyopharm Therapeutics

第10章分析师建议

升起和降落
综合机会图

第十一章参考文献与调查方法

参考
调查方法

简介目录

Product Code: CMI2399

The kidney cancer drugs market is estimated to be valued at USD 6.89 billion in 2024 and is expected to reach USD 10.31 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.

Figure 1. Kidney Cancer Drugs Market Share (%), By Region, 2024

Pharmaceutical analytical testing refers to the use of scientific techniques and methods to establish kidney cancer, also known as renal cell carcinoma. It is becoming one of the most common cancers globally. According to estimates, over 400,000 new cases are diagnosed worldwide each year. Risk factors associated with kidney cancer include tobacco use, obesity, hereditary factors, and exposure to certain toxins. While early-stage disease may present no symptoms, some patients may see blood in urine, flank pain, or an abdominal mass. Treatment options range from partial or radical nephrectomy for localized disease to targeted therapies or immunotherapy for advanced cases. Overall, the global kidney cancer drugs market is expected to grow significantly in the coming years as factors such as rising incidence of disease, improving patient access to advanced treatments, and robust pipeline of novel drugs continue to support the market growth.

Market Dynamics:

The global kidney cancer drugs market is driven by the rising prevalence of renal cell carcinoma worldwide. Growing risk factors, such as increasing geriatric population, rising obesity rates, and greater exposure to toxins at the workplace, are contributing to the rising disease incidence. Additionally, improving patient access to premium targeted therapies and immunotherapies in developed nations are supporting the market growth. At the same time, lengthy duration of treatment involving combinations of surgery, radiotherapy, and drug regimens is keeping patients dependent on maintenance therapies for longer duration. While the market sees lucrative growth opportunities, factors such as patent expiration of major drugs and market entry of generics could hamper the revenue stream of leading developers. Moreover, high pricing and affordability issues in developing nations restrict broader market access. Nevertheless, robust pipeline of molecules under clinical trials targeting different disease pathways offers potential for market expansion in future.

Key Features of the Study:

This report provides in-depth analysis of the global kidney cancer drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global kidney cancer drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Merck & Co., Pfizer Inc., Novartis AG, Bayer AG, Amgen, F. Hoffmann-La Roche Ltd, and Eisai Co. Ltd
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global kidney cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global kidney cancer drugs market

Detailed Segmentation-

By Therapy
- Targeted Therapy
- Immunotherapy
- Chemotherapy
By Pharmacological Class
- Angiogenesis Inhibitors
- mTOR Inhibitors
- Cytokines
- Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Pfizer Inc.
- Novartis AG
- Bristol-Myers Squibb Company
- Roche Holding AG (Genentech, Inc.)
- Bayer AG
- Exelixis, Inc.
- Merck & Co., Inc.
- Eisai Co., Ltd.
- Aveo Pharmaceuticals
- AstraZeneca PLC
- Ipsen Biopharmaceuticals, Inc.
- GlaxoSmithKline plc
- Abbott Laboratories Source
- Amgen Inc.
- Calithera Biosciences, Inc.
- Active Biotech
- Immatics Biotechnologies GmbH
- Karyopharm Therapeutics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Therapy
- Market Snapshot, By Pharmacological Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Kidney Cancer Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Kidney Cancer Drugs Market, By Therapy, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Targeted Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Immunotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Chemotherapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Kidney Cancer Drugs Market, By Pharmacological Class, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Angiogenesis Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
mTOR Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Cytokines
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Kidney Cancer Drugs Market, By Distribution Channel, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Kidney Cancer Drugs Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- 3D Systems
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bristol-Myers Squibb Company
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Roche Holding AG (Genentech, Inc.)
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Bayer AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Exelixis, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Merck & Co., Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Eisai Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Aveo Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AstraZeneca PLC
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Ipsen Biopharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- GlaxoSmithKline plc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Abbott Laboratories Source
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Calithera Biosciences, Inc.
- Active Biotech
- Immatics Biotechnologies GmbH
- Karyopharm Therapeutics

10. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

肾癌药物市场：依治疗方法、按药理学、按分销管道、按地区